Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Nivolumab (Primary) ; Pemetrexed (Primary) ; TG 4010 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene

Most Recent Events

  • 26 Mar 2022 This trial is completed in Belgium (End Date: 02 Nov 2020), according to European Clinical Trials Database record.
  • 23 Nov 2020 This trial has been completed in Hungary, according to European Clinical Trials Database record.
  • 16 Dec 2019 Planned End Date changed from 1 Sep 2020 to 1 Nov 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top